<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38028269</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">0513-5710</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Yonago acta medica</Title><ISOAbbreviation>Yonago Acta Med</ISOAbbreviation></Journal><ArticleTitle>A Strategic Translational Research System for Drug Discovery in Tottori University.</ArticleTitle><Pagination><StartPage>394</StartPage><EndPage>403</EndPage><MedlinePgn>394-403</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.33160/yam.2023.11.001</ELocationID><Abstract><AbstractText>The probability of successful drug discovery is declining, and research and development costs are increasing. To solve these problems, pharmaceutical companies tend to in-license seeds from venture companies and academia. Therefore, academia's role in drug discovery is extremely important. Tottori University started a "Next-Generation Research Support Project (Strategic Research Support Project)" in 2020, developing a translational research system to promote drug discovery. In this project, we established a research and development infrastructure, such as seed registration, construction of drug research and development support, and research fund allocation. The registered seed were converted into project, and the project implemented this research and development system, and evaluated and verified its results. Twenty-two seeds were converted into projects and portfolios were constructed. Research funds were allocated to eight prioritized projects. Each project raised the research and development stages. From the overall portfolio, one project with the Japan Agency for Medical Research and Development (AMED) Drug Discovery Booster Project, and three projects with Seeds A of the AMED Translational Research Strategic Promotion Program were adopted. Additionally, a new low-molecular weight chaperone drug against GM1-gangliosidosis was out-licensed to an overseas pharmaceutical company. The strength of this system was the strategic allocation of research funds and the accompanying support that leveraged internal and external resources with the PM and researchers at its core. This system achieved certain results in promoting drug discovery; however, resource optimization of specialized personnel needs to be strengthened in the future. In this report, we summarized the efforts of translational research in Japan and around the world. In addition, the translational research efforts of Japanese academia and Tottori University were compared and the current status was summarized.</AbstractText><CopyrightInformation>&#xa9;2023 Tottori University Medical Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Organization for Research Institute and Promotion, Tottori University, Yonago 683-8503, Japan and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Organization for Research Institute and Promotion, Tottori University, Yonago 683-8503, Japan and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Washijima</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Organization for Research Institute and Promotion, Tottori University, Yonago 683-8503, Japan and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueki</LastName><ForeName>Masaru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Organization for Research Institute and Promotion, Tottori University, Yonago 683-8503, Japan and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikuchi</LastName><ForeName>Noriyoshi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Organization for Research Institute and Promotion, Tottori University, Tottori 680-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takenaka</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Organization for Research Institute and Promotion, Tottori University, Yonago 683-8503, Japan and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawata</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Organization for Research Institute and Promotion, Tottori University, Tottori 680-8550, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Yonago Acta Med</MedlineTA><NlmUniqueID>0414002</NlmUniqueID><ISSNLinking>0513-5710</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug discovery</Keyword><Keyword MajorTopicYN="N">open innovation</Keyword><Keyword MajorTopicYN="N">translational research</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38028269</ArticleId><ArticleId IdType="pmc">PMC10674056</ArticleId><ArticleId IdType="doi">10.33160/yam.2023.11.001</ArticleId><ArticleId IdType="pii">2023.11.001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsuruya N,Kawashima T,Shiozuka M,Nakanishi Y,Sugiyama D. Academia&#x2013;industry Cooperation in the Medical Field: matching Opportunities in Japan. Clin Ther. 2018;40:1807-12. 10.1016/j.clinthera.2018.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2018.10.010</ArticleId><ArticleId IdType="pubmed">30415863</ArticleId></ArticleIdList></Reference><Reference><Citation>Araiso T. The structure and function of industry-academia-government cooperation system in USA and Europe. J Jpn Soc Intellect Prod. 2014;10:1-12. Japanese.</Citation></Reference><Reference><Citation>Sakurai M,Kakihara H. Toward the development of the Japanese pharmaceutical industry new drug. Farumashia. 2013;49:965-9. Japanese.</Citation></Reference><Reference><Citation>Scannell JW,Blanckley A,Boldon H,Warrington B. Diagnosing the decline in pharmaceutical R&amp;D efficiency. Nat Rev Drug Discov. 2012;11:191-200. 10.1038/nrd3681</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3681</ArticleId><ArticleId IdType="pubmed">22378269</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuhmacher A,Gassmann O,Bieniok D,Hinder M,Hartl D. Open innovation: A paradigm shift in pharma R&amp;D? Drug Discov Today. 2022;27:2395-405. 10.1016/j.drudis.2022.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2022.05.018</ArticleId><ArticleId IdType="pubmed">35643258</ArticleId></ArticleIdList></Reference><Reference><Citation>Translation [Internet]. MD: National Center for Advancing Translational Sciences; [cited 2023 Jun 22]. Available from: https://ncats.nih.gov/translation</Citation></Reference><Reference><Citation>Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov. 2010;9:867-82. 10.1038/nrd3251</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3251</ArticleId><ArticleId IdType="pubmed">21031002</ArticleId></ArticleIdList></Reference><Reference><Citation>Translational Research Strategic Promotion Program [Internet]. Tokyo: Japan Agency for Medical Research and Development; [cited 2023 Aug 2]. Available from: https://www.amed.go.jp/program/list/16/01/009.html</Citation></Reference><Reference><Citation>Translational research program [Internet]. Tokyo: Japan Agency for Medical Research and Development; [cited 2023 Aug 2]. Available from: https://www.amed.go.jp/program/list/16/01/012.html</Citation></Reference><Reference><Citation>Clinical and Translational Science Awards (CTSA) Program [Internet]. MD: National Center for Advancing Translational Science; [cited 2023 Aug 18]. Available from: https://ncats.nih.gov/ctsa</Citation></Reference><Reference><Citation>Fraunhofer Home Page [Internet]. Munich: Fraunhofer-Gesellschaft; [cited 2023 Aug 2]. Available from: https://www.fraunhofer.de/en.html</Citation></Reference><Reference><Citation>Catapult program Home Page [Internet]. UK: Catapult Network; [cited 2023 Aug 2]. Available from: https://catapult.org.uk/</Citation></Reference><Reference><Citation>Promote Intellectual Property education at universities. etc.; 2015. Nov [Internet]. Tokyo: Ministry of Education, Culture, Sports, Science and Technology; [cited 2023 Jun 22]. Available from: http://www.kantei.go.jp/jp/singi/titeki2/tyousakai/kensho_hyoka_kikaku/2016/sangyo_zaisan/dai2/siryou3.pdf</Citation></Reference><Reference><Citation>Intellectual property management at universities; 2016. [Internet]. Tokyo: Patent Agency; [cited 2023 Jun 22]. Available from: https://www.jpo.go.jp/news/kokusai/developing/training/textbook/document/index/64_Intellectual_Property_j.pdf</Citation></Reference><Reference><Citation>Global Enhancing Development of Global Entrepreneur Program (EDGE program) [Internet]. Tokyo: Ministry of Education, Culture, Sports, Science and Technology; FY2014-2016 [cited 2023 Jun 22]. Available from: https://www.mext.go.jp/a_menu/jinzai/edge/1400289.htm</Citation></Reference><Reference><Citation>Basis for Supporting Innovative Drug Discovery and Life Science Research(BINDS)[Internet]. Tokyo: Japan Agency for Medical Research and Development; [cited 2023 Jun 22]. Available from: https://www.binds.jp/</Citation></Reference><Reference><Citation>Self-evaluation report on performance in FY2021; 2022. Jun [Internet]. Tokyo: Japan Agency for Medical Research and Development; [cited 2023 Jun 22]. Available from: https://www.amed.go.jp/content/000100551.pdf</Citation></Reference><Reference><Citation>Translational Research Support Institute Accreditation System [Internet]. Tokyo: The Ministry of Education, Culture, Sports, Science and Technology; [cited 2023 Aug 2]. Available from: https://www.mext.go.jp/a_menu/kagaku/hashiwatashi/index.htm</Citation></Reference><Reference><Citation>Shimokawa H. The challenge of CRIETO to promote advanced medical innovation from the Tohoku region. Nippon Yakurigaku Zasshi. 2015;146:47-53. 10.1254/fpj.146.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/fpj.146.47</ArticleId><ArticleId IdType="pubmed">26165342</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada K. Efforts of open innovation for practical application of research seeds from academia. Farumashia. 2019;55:11-4. Japanese.</Citation></Reference><Reference><Citation>Furuya S. All-Japan drug discovery evolve from the construction and active utilization of networks -Open innovation strategy and network construction and utilization will become a new &#x201c;drug discovery&#x201d; paradigm that makes use of basic research capabilities in Japan-. Folia Pharmacol. Jpn. 2015;145:243-9. Japanese.10.1254/fpj.145.243</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/fpj.145.243</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida W. Aiming for Future Medicine and Healthcare: Tohoku University Open Innovation. MEDCHEM NEWS. 2019;29:154-60. Japanese.</Citation></Reference><Reference><Citation>Iida K,Ishida T,Nishimura N. Consideration on Academia Environments for Creating Medical Innovation. Yakugaku Zasshi. 2022;142:75-84. 10.1248/yakushi.21-00183</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/yakushi.21-00183</ArticleId><ArticleId IdType="pubmed">34629350</ArticleId></ArticleIdList></Reference><Reference><Citation>Research on the management and systems of industry-academia collaboration at overseas universities [Internet]. Tokyo: Ministry of Education, Culture, Sports, Science and Technology; [cited 2023 Aug 2]. Available from: https://www.mext.go.jp/a_menu/shinkou/sangaku/__icsFiles/afieldfile/2018/10/01/1409478_001_2.pdf and https://www.mext.go.jp/a_menu/shinkou/sangaku/__icsFiles/afieldfile/2018/10/01/1409478_002.pdf</Citation></Reference><Reference><Citation>&#x201c;Science and Technology Indicators,&#x201d; August 2019. [Internet]. Tokyo: National Institute of Science and Technology Policy; [cited 2023 Aug 2]. Available from: https:// www.nistep.go.jp/sti_indicator/2019/RM283_55.html</Citation></Reference><Reference><Citation>Ohyama S,Gohtani S. Techno Network Shikoku Co. Ltd (Shikoku TLO) as a wide area TLO. J. Jpn. Soc. Intel. Prod. 2022;19:7-12. Japanese.</Citation></Reference><Reference><Citation>Yuki Y. The history, current status, and share of dream by Niigata TLO. J. Jpn. Soc. Intel. Prod. 2022;19:13-20. Japanese.</Citation></Reference><Reference><Citation>Office of Pharmaceutical Industry Research. Probability of Success Analysis of Drug Discovery - Focusing on Clinical Trials. Policy Research Institute News. 2022;66.</Citation></Reference><Reference><Citation>Hay M,Thomas DW,Craighead JL,Economides C,Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40-51. 10.1038/nbt.2786</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2786</ArticleId><ArticleId IdType="pubmed">24406927</ArticleId></ArticleIdList></Reference><Reference><Citation>Avior Y,Sagi I,Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016;17:170-82. 10.1038/nrm.2015.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2015.27</ArticleId><ArticleId IdType="pubmed">26818440</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y,Inoue H,Wu JC,Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:115-30. 10.1038/nrd.2016.245</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.245</ArticleId><ArticleId IdType="pmc">PMC6416143</ArticleId><ArticleId IdType="pubmed">27980341</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of Pharmaceutical Industry Research. Trends in Drug Discovery Modalities in New Drugs - Diversification / Polymerization Trends and Evolving Small Molecular Drugs. Policy Research Institute News. 2021;64.</Citation></Reference><Reference><Citation>Japan Health Sciences Foundation. 2020. Domestic Basic Technology Survey Report &#x201c;Medical Needs Survey on 60 Diseases (6th)&#x201d; [Analysis]. 2020 Dec.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>